COVIFOR inj


Brand Name : COVIFOR inj
Pharmaceuticals : Hetero Drugs Limited
Generic Name :

Remdesivir for injection 100mg/vial or 5mg/ml

Type of Medicine : Antiviral
Uses :
  • Novel Coronavirus Infectious Disease (COVID-19)

Remdesivir has an FDA Emergency Use Authorization for use in adults and children with suspected or confirmed COVID-19 in hospital with an SpO2 ≤94%.13 This is not the same as an FDA approval.

The FDA Emergency Use Authorization suggests a loading dose of 200mg once daily in patients ≥ 40 kg or 5 mg/kg once daily in patients 3.5 kg to less than 40 kg, followed by a maintenance dose of 100mg once daily in patients ≥ 40 kg or 2.5 mg/kg once daily in patients 3.5 kg to less than 40 kg.13 Patients not needing invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) should be treated for 5 days (including the loading dose on day 1), up to 10 days if they do not show improvement.13 Patients requiring invasive mechanical ventilation or ECMO should be treated for 10 days.

Clinical trials used a regimen of 200mg once daily on the first day, followed by 100mg once daily for another 9 days.

Early data suggests that some patients may benefit from only 5 days of treatment.

Remdesivir was originally investigated as a treatment for Ebola virus, but has potential to treat a variety of RNA viruses.1 Its activity against the coronavirus (CoV) family of viruses, such as SARS-CoV and MERS-CoV, was described in 2017,2 and it is also being investigated as a potential treatment for SARS-CoV-2 infections.

Side Effects :

N/A

Contraindications :

N/A

Doses Form Available :

Injection, powder, lyophilized, for solution

Dose Available :
  • 5 mg/1mL
  • 100mg/1mL?

Remdesivir, or GS-5734, is an adenosine triphosphate analog first described in the literature in 2016 as a potential treatment for Ebola.1 In 2017, its activity against the coronavirus family of viruses was also demonstrated.2 Remdesivir is also being researched as a potential treatment to SARS-CoV-2, the coronavirus responsible for COVID-19

Remdesivir was granted an FDA Emergency Use Authorization on 1 May 2020.11 This is not the same as an FDA approval

Thumb

Mechanism of action
Remdesivir is a nucleoside analog that is expected to inhibit the action of RNA polymerase.3 By incorporating into RNA, additional nucleotides cannot be added, terminating RNA transcription.

Viruses with mutations in RNA polymerase to develop partial resistance to remdesivir have been shown to be less infective.

TARGET ACTIONS ORGANISM
UReplicase polyprotein 1ab
inhibitor
SARS-CoV
URNA-directed RNA polymerase L
inhibitor
Zaire ebolavirus (strain Mayinga-76)

Precautions :

N/A

Related Medicines
Remdesivir inj ,

Remdesivir

Jubi-R inj ,

Remdesivir for injection 100mg/vial or 5mg/ml

Remivir inj ,

Remdesivir for injection 100mg/vial or 5mg/ml

Cipremi inj ,

Remdesivir for injection 100mg/vial or 5mg/ml